OncoMatch/Clinical Trials/NCT04025450
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
Is NCT04025450 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Chidamide+VRD and VRD for multiple myeloma.
Treatment: Chidamide+VRD · VRD — In the phase I trial, dose escalation of chidamide will be performed at 4 different dosages (15mg, 20mg, 25mg, 30mg) for optimal dosage, in the phase II trial, the safety and efficacy of chidamide+VRD will be compared with that of VRD regimen.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Disease stage
Required: Stage RISS-3 (RISS)
RISS-3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chidamide, bortezomib, lenalidomide, dexamethasone (any of the experimental regimen) (chidamide, bortezomib, lenalidomide, dexamethasone)
Exception: pain-relieving radiotherapy is allowed
Having received any of the medicine of the experiment regimen within 30 days prior to enrollment, pain-relieving radiotherapy is allowed
Lab requirements
Blood counts
Neutrophil count≥1.5×10^9/L, platelet count≥50×10^9/L
Kidney function
eGFR≥40ml/min, except in the case of myeloma-related nephropathy
Liver function
ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum
Cardiac function
Normal left ventricular ejection rate, NYHA stage 1
ALT/AST level <2.5 times of the maximum of normal range; total bilirubin<1.5 times of normal maximum; Neutrophil count≥1.5×10^9/L, platelet count≥50×10^9/L; eGFR≥40ml/min, except in the case of myeloma-related nephropathy; Normal left ventricular ejaculation rate, NYHA stage 1, pulmonary function GOLD stage 1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify